AI model identifies SARS-CoV-2 from blood tests, chest x-rays

An artificial intelligence (AI) model that analyzed data from blood tests an...Read more on AuntMinnie.comRelated Reading: Vuno inks deal with Samsung integrating AI with mobile x-ray AI may predict heart disease risk on chest x-ray Chest x-ray may predict risk of hospitalization in COVID-19 AI of x-ray predicts prognosis of COVID-19 patients Daily chest x-rays not needed in COVID-19 patients
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

On Sept. 7, the country’s leading COVID-19 doctor issued a dire warning about the growing number of pandemic cases in the country, and the shrinking number of ICU beds available to care for the sickest people. Speaking on CNN, Dr. Anthony Fauci, the chief White House medical advisor, said we are “perilously close in certain areas of the country of getting so close to having full occupancy that you’re going to be in a situation where you’re going to have to make some tough choices.” Those tough choices, he admitted, include discussions about whether scarce resources should go to people who have...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
AbstractIntroductionYoung and middle-aged adults are the largest group of patients infected with SARS-CoV-2 and some of them develop severe disease.ObjectiveTo investigate clinical manifestations in adults aged 18 –65 years hospitalized for COVID-19 and identify predictors of poor outcome. Secondary objectives: to explore differences compared to the disease in elderly patients and the suitability of the commonly used community-acquired pneumonia prognostic scales in younger populations.MethodsMulticenter prospective registry of consecutive patients hospitalized for COVID-19 pneumonia aged 18 –65 years...
Source: Infection - Category: Infectious Diseases Source Type: research
CONCLUSION: Poor outcomes of COVID-19 disease were observed in patients with IPF after robust matching of confounders. Our data confirm that patients with IPF constitute a high-risk cohort for poor outcomes related to COVID-19 disease.PMID:34376400 | DOI:10.1136/bmjresp-2021-000969
Source: Respiratory Care - Category: Respiratory Medicine Authors: Source Type: research
This article provides the first data on risk and severity of SARS-CoV-2 infections among study participants for the time period between 30 May 2020 and 5 March 2021.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Research letters Source Type: research
This study utilizes a continuously updated Electronic Medical Record (EMR) network to assess the possible benefits of influenza vaccination mitigating critical adverse outcomes in SARS-CoV-2 positive patients from 56 healthcare organizations (HCOs). MethodsThe de-identified records of 73,346,583 patients were retrospectively screened. Two cohorts of 37,377 patients, having either received or not received influenza vaccination six months –two weeks prior to SARS-CoV-2 positive diagnosis, were created using Common Procedural Terminology (CPT) and logical observation identifiers names and codes (LOINC) codes. Adverse ou...
Source: PLoS One - Category: Biomedical Science Authors: Source Type: research
Thomas A. FireyCOVID-19hospitalizations anddeaths are rising in the United States as the highly infectious Delta variant of the SARS-CoV-2 virus has becomethe dominant strain in the country. These serious cases arealmost entirely limited to people who are not vaccinated against the virus; for the vaccinated,infection rates are much lower and nearly all infections are no more troublesome than a cold or — at worst – a bout of the flu, and often go unnoticed altogether.COVID-19 causedat least11 percent of all U.S. deaths in 2020, making it thethird leading cause of death, behind only heart disease and cancer. So f...
Source: Cato-at-liberty - Category: American Health Authors: Source Type: blogs
Getting the kids ready to go back to school each fall is stressful enough in a normal year, never mind in the midst of a pandemic. Between the more transmissible Delta coronavirus variant, rising cases across the country and new masking guidance from the U.S. Centers for Disease Control and Prevention (CDC), there’s a lot for parents to navigate as they plan for schools to reopen this August and September. On the whole, experts seem to agree it’s time to get kids back into their classrooms. Remote learning set many children—especially students of color—back academically, cut them off from essential ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
Lancet Respir Med. 2021 Jul 27:S2213-2600(21)00310-6. doi: 10.1016/S2213-2600(21)00310-6. Online ahead of print.ABSTRACTBACKGROUND: Doxycycline is often used for treating COVID-19 respiratory symptoms in the community despite an absence of evidence from clinical trials to support its use. We aimed to assess the efficacy of doxycycline to treat suspected COVID-19 in the community among people at high risk of adverse outcomes.METHODS: We did a national, open-label, multi-arm, adaptive platform randomised trial of interventions against COVID-19 in older people (PRINCIPLE) across primary care centres in the UK. We included peo...
Source: Respiratory Care - Category: Respiratory Medicine Authors: Source Type: research
Respir Med. 2021 Jul 22;187:106538. doi: 10.1016/j.rmed.2021.106538. Online ahead of print.ABSTRACTBACKGROUND: Analyses of COVID-19 infection outcomes in patients with preexisting pulmonary sarcoidosis are lacking and are limited to case reports or small case series with the largest study reporting outcomes of 37 patients.RESEARCH QUESTION: Retrospective cohort study to assess clinical outcomes of 945 patients with pulmonary sarcoidosis, presenting with COVID 19, compared to a propensity matched cohort of patients without sarcoidosis.STUDY DESIGN AND METHODS: Analysis of a multi-center research network TriNETX was performe...
Source: Respiratory Care - Category: Respiratory Medicine Authors: Source Type: research
d Nadler Prata In November 2020, Brazil ranked third in the number of cases of coronavirus disease 2019 (COVID-19) and second in the number of deaths due to the disease. We carried out a descriptive study of deaths, mortality rate, years of potential life lost (YPLL) and excess mortality due to COVID-19, based on SARS-CoV-2 records in SIVEP-Gripe (Ministry of Health of Brazil) from 16 February 2020, to 1 January 2021. In this period, there were 98,025 deaths from COVID-19 in Brazil. Men accounted for 60.5% of the estimated 1.2 million YPLLs. High YPLL averages showed prematurity of deaths. The population aged 45–...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
More News: Cardiology | COVID-19 | Heart | Heart Disease | Heart Transplant | Radiology | SARS | X-Ray